Olink Holding (OLK)
(Delayed Data from NSDQ)
$24.40 USD
-0.02 (-0.08%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $24.40 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
OLK 24.40 -0.02(-0.08%)
Will OLK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for OLK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OLK
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Lags Revenue Estimates
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
OLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates
Company News for Nov 16, 2023
Tivic Health Systems, Inc. (TIVC) Reports Q3 Loss, Misses Revenue Estimates
Other News for OLK
Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
Olink announces publication of study using Olink Explore
Lab Instrument Industry Update - New Commercial Entrants
Balanced Outlook: Holding Olink Amidst Growth Potential and Regulatory Uncertainties